MSI2 and cancer: This discrepancy between bulk RNA–Seq and IHC data could result from a minor presence of MSI1+ cancer stem cells (CSCs) in these tumors or a potential cross–reactivity of the MSI1–directed antibodies with MSI2 [69,72,73,74,75].